Guillain–Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data

[1]  C. Mhiri,et al.  Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases , 2021, Neurological Sciences.

[2]  M. Makris,et al.  Vaccine-induced immune thrombotic thrombocytopenia , 2021, The Lancet Haematology.

[3]  Jerome H. Kim,et al.  Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database , 2021, Journal of medical virology.

[4]  T. Vial,et al.  Adenovirus COVID‐19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis , 2021, Annals of neurology.

[5]  K. Khunti,et al.  Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[6]  M. Hung,et al.  Guillain-Barré Syndrome Associated with COVID-19 Vaccination , 2021, Emerging infectious diseases.

[7]  E. Woo,et al.  Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. , 2021, JAMA.

[8]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[9]  P. Ripellino,et al.  Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase , 2021, Vaccines.

[10]  I. Potasman,et al.  Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2. , 2021, JAMA neurology.

[11]  Ehrenstein,et al.  Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines , 2021 .

[12]  Ben Y. Reis,et al.  Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting , 2021, The New England journal of medicine.

[13]  E. Woo,et al.  Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  G. Reyes-Terán,et al.  Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine , 2021, Clinical Immunology.

[15]  P. Tighe,et al.  Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination , 2021, Annals of neurology.

[16]  A. Naska,et al.  Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis , 2021, European journal of neurology.

[17]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[18]  P. Espinosa,et al.  Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine , 2021, Cureus.

[19]  H. Tumani,et al.  Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases , 2020, Journal of Neurology.

[20]  S. Farmer,et al.  Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome , 2020, medRxiv.

[21]  J. Dáňová,et al.  Is an Increased Risk of Developing Guillain–Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis , 2020, Vaccines.

[22]  F. Ma,et al.  Vaccines and the risk of Guillain-Barré syndrome , 2019, European Journal of Epidemiology.

[23]  N. Andrews,et al.  Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain–Barré Syndrome and Narcolepsy , 2019, CNS Drugs.

[24]  S. Esposito,et al.  Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. , 2019, Vaccine.

[25]  F. Bolgert,et al.  Guillain‐Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008–2013) , 2017, Journal of the peripheral nervous system : JPNS.

[26]  V. Bauchau,et al.  Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccines† , 2015, Pharmacoepidemiology and drug safety.

[27]  H. Hartung,et al.  Risk of Guillain–Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany , 2014, Pharmacoepidemiology and drug safety.

[28]  Judith Drenthen,et al.  Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. , 2014, Brain : a journal of neurology.

[29]  S. Sheikh,et al.  Guillain-Barré Syndrome Incidence in a Large United States Cohort (2000–2009) , 2012, Neuroepidemiology.

[30]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[31]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[32]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[33]  Nicholas Moore,et al.  Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole , 2003, Pharmacoepidemiology and drug safety.

[34]  W. Inman,et al.  Under-reporting of adverse drug reactions. , 1985, British medical journal.